Search results for "Gonadotropin-releasing hormone"

showing 10 items of 52 documents

Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist…

2005

Background This descriptive study evaluates the impact on endometrial development of standard and high doses of a GnRH antagonist in stimulated cycles compared with GnRH agonist and natural cycles. Methods Thirty-one oocyte donors were treated with a combination of rFSH and 0.25 mg/day ganirelix (standard dose), 2 mg/day ganirelix (high dose) or 0.6 mg/day buserelin (long protocol). Vaginal progesterone (200 mg/day) was administered in the luteal phase. Endometrial biopsies were performed 2 and 7 days after HCG administration. Additional biopsies were carried out in a subset of 12 subjects, 2 and 7 days following the LH peak of their previous natural cycle. Biopsies were evaluated histologi…

AgonistAdultendocrine systemmedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classmedicine.medical_treatmentFertilization in VitroLuteal phaseBiologyLuteal PhaseEndometriumBuserelinChorionic GonadotropinGonadotropin-releasing hormone antagonistGonadotropin-Releasing HormoneEndometriumOvulation InductionInternal medicinemedicineHumansUltrasonicsGanirelixOligonucleotide Array Sequence Analysismedicine.diagnostic_testOocyte DonationRehabilitationObstetrics and GynecologyBuserelinmedicine.anatomical_structureEndocrinologyReproductive MedicineGene Expression RegulationReceptors EstrogenMicroscopy Electron ScanningOocytesRNAOvulation inductionFemaleFollicle Stimulating HormoneReceptors Progesteronehormones hormone substitutes and hormone antagonistsmedicine.drugEndometrial biopsyHuman reproduction (Oxford, England)
researchProduct

Pretreatment with gonadotropin-releasing hormone (GnRH) antagonists to prevent the flare-up effect of long-acting GnRH agonists: results of a pilot s…

2007

This study evaluated in vivo whether the flare-up effect of GnRH agonists can be suppressed through pretreatment with a GnRH antagonist. The classic flare-up effect caused by 3.8 mg goserelin acetate could not be suppressed through pretreatment using a single dosage of 3.24 mg cetrorelix acetate.

AgonistMaleendocrine systemmedicine.medical_specialtyTime Factorsmedicine.drug_classPilot ProjectsGonadotropin-releasing hormoneGonadotropin-Releasing HormoneHormone AntagonistsIn vivoInternal medicinemedicineFlare upHumansTestosteroneEstradiolbusiness.industryGoserelin AcetateAntagonistObstetrics and GynecologyLuteinizing HormoneLong actingEndocrinologyTreatment OutcomeReproductive MedicineCetrorelixGoserelinFemaleFollicle Stimulating Hormone Humanbusinesshormones hormone substitutes and hormone antagonistsTranssexualismmedicine.drugFertility and sterility
researchProduct

The role of gonadotropin-releasing hormone in murine preimplantation embryonic development.

1999

Previous studies have established the presence of an extrahypothalamic GnRH in a variety of tissues. GnRH receptor is known to be present in the placenta, which produces and secretes the decapeptide from the very early stages of placentation. We hypothesized that GnRH may play a role in the preimplantation development of embryos. To examine this hypothesis, we assessed GnRH and GnRH receptor messenger RNA (mRNA; RT-PCR) and protein expression (Immunohistochemistry) in preimplantation murine embryos at various developmental stages. Furthermore, preimplantation murine embryos were cultured with GnRH agonist and antagonist in vitro to assess the influence of GnRH analogs on embryo development.…

Agonistendocrine systemmedicine.medical_specialtyanimal structuresTranscription Geneticmedicine.drug_classZygoteMice Inbred StrainsGonadotropin-releasing hormoneBiologyMorulaGonadotropin-Releasing HormoneEmbryonic and Fetal DevelopmentMiceEndocrinologyInternal medicinePlacentamedicineAnimalsBlastocystRNA MessengerMessenger RNAReverse Transcriptase Polymerase Chain ReactionEmbryogenesisPlacentationGene Expression Regulation DevelopmentalEmbryoEndocrinologymedicine.anatomical_structureBlastocystembryonic structureshormones hormone substitutes and hormone antagonistsReceptors LHRHEndocrinology
researchProduct

Hormonal and metabolic adaptation to fasting: effects on the hypothalamic-pituitary-ovarianaxis and reproductive performance of rabbit does

2006

To assess the impact of acute caloric shortage on reproduction, rabbit does were either fed ad libitum (control, AL), or fasted for 24 (STF) or 48 h (LTF) before induction of ovulation with GnRH injection. Blood samples were collected during the last 3 h of fasting, and the following 4 h after GnRH injection, when feed was provided again, to measure plasma concentrations of LH, estradiol-17β, leptin, insulin, T3, corticosterone, glucose, and NEFA. Before re-feeding, plasma leptin, insulin, and T3 concentrations were lower (P ≤ 0.01) in both fasted groups than in controls, but then gradually increased following realimentation to match those of controls. During fasting, corticoster…

Blood GlucoseLHHypothalamo-Hypophyseal Systemmedicine.medical_specialtymedia_common.quotation_subjectmedicine.medical_treatmentPituitary-Adrenal SystemHypothalamic–pituitary–gonadal axisGonadotropin-releasing hormoneBiologyGonadotropin-Releasing HormoneRandom Allocationchemistry.chemical_compoundLEPTINEndocrinologyNEFAOvulation InductionFood AnimalsPregnancyRABBITCorticosteroneInternal medicineFASTINGmedicineAnimalsOvulationmedia_commonEstradiolReproductionLeptinInsulinOvaryEstradiol-17Luteinizing HormoneT3INSULINHormonesEndocrinologychemistryTriiodothyronineFemaleAnimal Science and ZoologyRabbitsCorticosteroneLuteinizing hormone
researchProduct

Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a pr…

2013

PURPOSE To assess the efficacy of gonadotropin-releasing hormone agonist (GnRHa) in preventing chemotherapy-induced ovarian failure in patients treated for Hodgkin or non-Hodgkin lymphoma within the setting of a multicenter, randomized, prospective trial. PATIENTS AND METHODS Patients age 18 to 45 years were randomly assigned to receive either the GnRHa triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) concomitantly with alkylating agents containing chemotherapy. The primary end point was the premature ovarian failure (POF) rate (follicle-stimulating hormone [FSH] ≥ 40 IU/L) after 1 year of follow-up. Results Eighty-four of 129 randomly assigned patients …

Cancer ResearchTime FactorsLymphomamedicine.medical_treatmentGonadotropin-Releasing Hormone -- agonistsPrimary Ovarian InsufficiencyTriptorelin Pamoate -- therapeutic uselaw.inventionGonadotropin-Releasing HormoneGynécologieRandomized controlled triallawAntineoplastic Combined Chemotherapy ProtocolsClinical endpointBiological Markers -- bloodNorethindrone -- therapeutic useProspective StudiesTreatment FailureProspective cohort studyTriptorelin PamoateEstradiolLymphoma Non-HodgkinLymphoma -- drug therapyMiddle AgedTriptorelinHodgkin DiseasePremature ovarian failureLuteolytic AgentsOncologyHodgkin Disease -- drug therapyDrug Therapy CombinationFemaleEstradiol -- bloodmedicine.drugAdultAntineoplastic Combined Chemotherapy Protocols -- administration & dosage -- adverse effectsmedicine.medical_specialtyNorethisteronemedicine.drug_classUrologyFollicle Stimulating Hormone -- bloodGonadotropin-releasing hormone agonistmedicineHumansGynecologyChemotherapybusiness.industrymedicine.diseaseLuteolytic Agents -- therapeutic useCancérologieLymphoma Non-Hodgkin -- drug therapyPremenopausePrimary Ovarian Insufficiency -- blood -- chemically induced -- prevention & controlFollicle Stimulating HormoneNorethindronebusinessBiomarkersFollow-Up Studies
researchProduct

Neonatal Outcomes and Long-Term Follow-Up of Children Born from Frozen Embryo, a Narrative Review of Latest Research Findings

2022

In recent years, the growing use of ART (assisted reproductive techniques) has led to a progressive improvement of protocols; embryo freezing is certainly one of the most important innovations. This technique is selectively offered as a tailored approach to reduce the incidence of multiple pregnancies and, most importantly, to lower the risk of developing ovarian hyperstimulation syndrome when used in conjunction with an ovulation-triggering GnRH antagonist. The increase in transfer cycles with frozen embryos made it possible to study the effects of the technique in children thus conceived. Particularly noteworthy is the increase in macrosomal and LGA (large for gestational age) newborns, i…

Cryopreservationfresh embryo transferReproductive Techniques Assistedcryopreservation; fresh embryo transfer; frozen embryo transfer; neonatal outcomes; vitrificationInfant NewbornGeneral MedicineEmbryo TransferSettore MED/40 - Ginecologia E OstetriciavitrificationGonadotropin-Releasing HormonePregnancyneonatal outcomesHumansFemalefrozen embryo transferChildFollow-Up StudiesMedicina
researchProduct

Hypogonadism in β-thalassemic adolescents: A characteristic pituitary-gonadal impairment. The ineffectiveness of long-term iron chelation therapy

1990

The pituitary-gonadal function was studied in 18 beta-thalassemic female adolescents, 8 with delayed puberty and 10 with primary amenorrhea,treated with repeated transfusions and long-term iron chelation therapy by subcutaneous infusion. A 100 micrograms gonadotropin-releasing hormone (GnRH) test, a double-bolus GnRH test after estradiol administration in non-responders, a 400 micrograms thyrotropin-releasing hormone (TRH) test and a 'high dose' human menopausal gonadotropin (hMG) test were performed. LH and FSH peak levels were significantly lower in thalassemic patients than in controls, both in the 100 micrograms GnRH test (LH was 4.3 +/- 0.7 mIU/ml vs 40.8 +/- 6.0 mIU/ml and FSH 3.3 +/-…

Delayed pubertyendocrine systemmedicine.medical_specialtyMenotropinsAdolescentendocrine system diseasesmedicine.drug_classIronEndocrinology Diabetes and MetabolismDeferoxamineGonadotropin-Releasing HormoneGnrh testEndocrinologyTRH stimulation testInternal medicinemedicineHumansChildThyrotropin-Releasing HormoneDose-Response Relationship DrugEstradiolbiologybusiness.industryHypogonadismOvaryObstetrics and GynecologyIron chelation therapyLuteinizing HormoneChelation TherapyProlactinProlactinEndocrinologyPituitary GlandHMG-CoA reductasebiology.proteinThalassemiaFemaleFollicle Stimulating Hormonemedicine.symptomGonadotropinbusinesshormones hormone substitutes and hormone antagonistsHormoneGynecological Endocrinology
researchProduct

Melatonin modulates diacylglycerol and arachidonic acid metabolism in the anterior pituitary of immature rats.

1990

In pituitary glands of immature rats prelabeled in vitro with [3H]arachidonic acid, melatonin diminished the luteinizing hormone-releasing hormone (LHRH)-induced increase in [3H]diacylglycerol accumulation as well as [3H]arachidonic acid release from the tissue. Melatonin reduced also LHRH-stimulated incorporation of [3H]glycerol into pituitary [3H]diacylglycerol. The effect was day-time dependent: in the evening experiment melatonin was effective at 0.1 nM concentration while in the morning it had no effect even at 10 nM concentration. The effect of melatonin was also abolished by pretreatment with pertussis toxin. Diacylglycerol and/or arachidonic acid might serve as 2nd messengers transd…

Glycerolendocrine systemmedicine.medical_specialtyPituitary glandArachidonic AcidsBiologyPertussis toxinGlyceridesMelatoninDiglyceridesGonadotropin-Releasing Hormonechemistry.chemical_compoundAnterior pituitaryPituitary Gland AnteriorInternal medicinemedicineAnimalsDiacylglycerol kinaseMelatoninArachidonic AcidGeneral NeuroscienceRats Inbred StrainsMetabolismRatsmedicine.anatomical_structureEndocrinologychemistryArachidonic acidFemalehormones hormone substitutes and hormone antagonistsHormonemedicine.drugNeuroscience letters
researchProduct

Serum luteinizing hormone in patients undergoing ovarian stimulation with gonadotropin-releasing hormone antagonists and recombinant follicle-stimula…

2004

The serum LH was determined on days 3, 6, and 8 of stimulation and on the day of hCG in 110 normogonadotropic patients undergoing controlled ovarian hyperstimulation (COH) for IVF induced with GnRH antagonists and recombinant FSH, creating three groups of patients according to Tukey's hinges (percentiles 25 and 75) for each determination. No differences were observed between the number of oocytes recovered or the fertilization, implantation, and pregnancy rates (PR) of the groups, although patients with high serum LH levels during stimulation showed significantly higher serum E2 levels on the day of hCG.

InfertilityAdultendocrine systemmedicine.medical_specialtyAdolescentStimulationGonadotropin-releasing hormoneControlled ovarian hyperstimulationBiologyCohort StudiesGonadotropin-Releasing HormoneFollicle-stimulating hormoneOvulation InductionInternal medicinemedicineHumansProspective StudiesMenstrual CyclePregnancyAntagonistObstetrics and GynecologyLuteinizing Hormonemedicine.diseaseRecombinant ProteinsEndocrinologyReproductive MedicineFemaleFollicle Stimulating Hormone HumanLuteinizing hormoneInfertility Femalehormones hormone substitutes and hormone antagonistsFertility and sterility
researchProduct

The effect of cancer treatment on female fertility and strategies for preserving fertility.

2006

Aggressive chemotherapy and radiotherapy in young patients with cancer has greatly enhanced the life expectancy of these patients, but these treatments often cause infertility because of the massive destruction of the ovarian reserve resulting in premature ovarian failure (POF). This review focuses on the effect of cancer treatments on fertility and on the various surgical and assisted-reproduction innovations that are available to provide the patient with the option of future pregnancies. As the emerging discipline of fertility preservation is steadily attracting increasing interest, developments in the near future promise to be very exciting. However, in everyday routine work, better inte…

InfertilityAdultmedicine.medical_specialtyReproductive Techniques Assistedmedicine.medical_treatmentmedia_common.quotation_subjectFertilityAntineoplastic AgentsPrimary Ovarian InsufficiencyGonadotropin-Releasing HormoneNeoplasmsmedicineHumansFertility preservationIntensive care medicineOvarian reserveRadiation Injuriesmedia_commonCryopreservationbusiness.industryOvaryObstetrics and GynecologyCancermedicine.diseasePremature ovarian failureSurgeryRadiation therapyFertilityReproductive MedicineLife expectancyOocytesFemalebusinessInfertility FemaleEuropean journal of obstetrics, gynecology, and reproductive biology
researchProduct